An LPS-functionalized nanoplatform facilitating immune re-education and NET suppression for eradication of postoperative residual tumors in ovarian cancer

The prognosis of patients with ovarian cancer (OC) after standardized cytoreductive surgery plus platinum-based chemotherapy is still poor owing to minimal residual tumors and the immunosuppressive “cold tumor” microenvironment. Furthermore, inefficient drug delivery and neutrophil extracellular trap (NET)-driven metastasis lead to worse survival. Therefore, the development of a multifunctional drug that can overcome these obstacles in postoperative OC therapy is urgently needed. A lipopolysaccharide (LPS)-functionalized nanocarrier (L-Lip@CC) was engineered to co-deliver cisplatin (CDDP) and specific peptidylarginine deiminases 4 (PAD4) inhibitor Cl-amidine. Its neutrophil hitchhiking delivery, re-educating immune cells, and inhibiting NET formation were evaluated in vitro and in toll-like receptor 4 (TLR4) knockout mice. The efficacy of NET blockade in inhibiting OC metastasis was verified in PAD4 knockout mice. Therapeutic efficacy and safety were validated in OC cell cultures, as well as in orthotopic and metastatic OC mouse models. L-Lip@CC can in situ hitchhike circulating neutrophils via TLR4, thus being precisely delivered to postoperative residual tumors and exerting strong cytotoxicity through DDP. The LPS decorated on the surface of L-Lip@CC reduces the toxicity of free LPS while maintaining superior immunomodulatory capacity. Therefore, L-Lip@CC effectively re-educates antitumor immunity by increasing the infiltration of CD8 + T cells and NK cells, promoting M1-like polarization of tumor-associated macrophages (TAMs), while also effectively inhibiting NETs formation via Cl-amidine, thereby preventing the establishment of a metastatic niche. Collectively, this multifunctional nanoplatform achieves tumor-targeted delivery, thereafter offers a highly promising therapeutic strategy for OC after cytoreductive surgery.

Authors

Institutions

Publication Details

Journal
Journal of Nanobiotechnology
Published
2026-11-16
DOI
https://doi.org/10.1186/s12951-026-05196-2
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

An LPS-functionalized nanoplatform facilitating immune re-education and NET suppression for eradication of postoperative residual tumors in ovarian cancer

Heming Sun, Dingqing Feng, Suying Xu, Ming Xue et al.
8 links
Journal of Nanobiotechnology
Nanoparticle-Based Drug Delivery
article

An LPS-functionalized nanoplatform facilitating immune re-education and NET suppression for eradication of postoperative residual tumors in ovarian cancer

Heming Sun, Dingqing Feng, Suying Xu, Ming Xue, Chang Zhou, Wenhui Wang, Xiaoyu Deng, Huan Yu, Caiyao Chen, Chunhong Rong, Jie Wei, Leyu Wang, Yuebo Li, Jing Liang, Bin Ling, Qingxia Zhang
article en

Abstract

The prognosis of patients with ovarian cancer (OC) after standardized cytoreductive surgery plus platinum-based chemotherapy is still poor owing to minimal residual tumors and the immunosuppressive “cold tumor” microenvironment. Furthermore, inefficient drug delivery and neutrophil extracellular trap (NET)-driven metastasis lead to worse survival. Therefore, the development of a multifunctional drug that can overcome these obstacles in postoperative OC therapy is urgently needed. A lipopolysaccharide (LPS)-functionalized nanocarrier (L-Lip@CC) was engineered to co-deliver cisplatin (CDDP) and specific peptidylarginine deiminases 4 (PAD4) inhibitor Cl-amidine. Its neutrophil hitchhiking delivery, re-educating immune cells, and inhibiting NET formation were evaluated in vitro and in toll-like receptor 4 (TLR4) knockout mice. The efficacy of NET blockade in inhibiting OC metastasis was verified in PAD4 knockout mice. Therapeutic efficacy and safety were validated in OC cell cultures, as well as in orthotopic and metastatic OC mouse models. L-Lip@CC can in situ hitchhike circulating neutrophils via TLR4, thus being precisely delivered to postoperative residual tumors and exerting strong cytotoxicity through DDP. The LPS decorated on the surface of L-Lip@CC reduces the toxicity of free LPS while maintaining superior immunomodulatory capacity. Therefore, L-Lip@CC effectively re-educates antitumor immunity by increasing the infiltration of CD8 + T cells and NK cells, promoting M1-like polarization of tumor-associated macrophages (TAMs), while also effectively inhibiting NETs formation via Cl-amidine, thereby preventing the establishment of a metastatic niche. Collectively, this multifunctional nanoplatform achieves tumor-targeted delivery, thereafter offers a highly promising therapeutic strategy for OC after cytoreductive surgery.

Journal of Nanobiotechnology
University of Science and Technology of China (CN), Capital Medical University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), China-Japan Friendship Hospital (CN), Peking Union Medical College Hospital (CN), Beijing Friendship Hospital (CN), Beijing Obstetrics and Gynecology Hospital (CN), State Key Laboratory of Chemical Resource Engineering (CN), Beijing University of Chemical Technology (CN)
National Natural Science Foundation of China
Good health and well-being
Nanoparticle-Based Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon